Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Patent
1997-02-27
1999-11-23
Kumar, Shailendra
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
514545, 514681, 514724, 514730, 560 51, 560 53, 564169, 568327, 568808, A61K 31165, C07C23305
Patent
active
059901721
ABSTRACT:
This invention provides peptidomimetics which bind to T4 or CD4 cell receptors and are useful in inhibiting viral infectivity by viruses which bind to T4 cell receptors. More specifically, peptidomimetics of this invention can alleviate symptoms of AIDS by inhibiting binding of HIV, the virus associated with AIDS, to receptor sites in human cells susceptible to HIV infection. These peptidomimetics, in particular, inhibit binding of HIV to cells of brain membrane and the immune system. They also display substantially longer half-lives in vivo than peptide T. The compounds of this invention which bind to T4 or CD4 receptors and thereby inhibit binding of HIV, alone or in combination with one another, can be used to alleviate AIDS symptoms and ameliorate symptoms of HIV infection, especially neuronal dementias and Kaposi's sarcoma. The compounds of this invention, alone or in combination, can further be used to prevent development of AIDS in persons who might become exposed to HIV.
REFERENCES:
patent: 4442090 (1984-04-01), Kakeya et al.
patent: 4835192 (1989-05-01), Johnson et al.
patent: 5162499 (1992-11-01), Trampota et al.
patent: 5210228 (1993-05-01), Todd et al.
patent: 5276016 (1994-01-01), Pert et al.
patent: 5308864 (1994-05-01), Lewis et al.
CA 63:4341 h, 1965.
Abdel-Meguid, S.S. et al. (1994), "An Orally Biovailable HIV-1 Protease Inhibitor Containing an Imidazole-Derived Peptide Bond Reaplcement: Crystallographic and Pharmacokinetic Analysis," Biochemistry 33(39):11671-11677.
Ayuso, J.L. (1994), "Use of Psychotropic Drugs in Patients with HIV Infection," Drugs 47(4):599-610.
Brenneman et al. (1988), "Peptide T Sequences Prevent Neuronal Cell Death Produced by the Envelope Protein (gp120) of the Human Immunodeficiency Virus," Drug Dev. Res. 15(4):361-369.
Buzy et al. (1992), "Potent gp120-like neurotoxic activity in the cerebrospinal fluid of HIV-infected individuals is blocked by peptide T," Brain Res. 598:10-18.
Caglioti (1996), "The reduction of tosylhydrazones and of acyl tosylhydrazides," Tetrahedron 22:487-493.
Carucci, J.E. et al. (1989), "Blocking of the nucleotide exchange of the P21 protein with an active site affinity label," Med. Sci. Res. 17:559-560.
Chen (1989), "Comparitive X-ray Crystallographic Evidence for a .beta.-Bend Conformation as the Active Structure for Peptide T in T4 Receptor Recognition," J. Protein Chem. 8:87-100.
Connell, E.V. et al. (Feb. 1994), "Combinative interactions of a human immunodeficiency virus (HIV) Tat antagonist with HIV reverse transcriptase inhibitors and an HIV protease inhibitor," Antimicrob. Agents Chemother. (US) 38 (2):348-52.
Dorsey, B.D. et al. (1994), "The Design of a Potent and Orally Bioavailable HIV Protease Inhibitor," J. Med. Chem. 37:(21):3443-3451.
Dreiding et al. (1955), "A Synthesis of trans-10-Methyl-2-decalone," J. Am. Chem. Soc. 77:411-414.
Ito et al. (1978), "Synthesis of .alpha.,.beta.-Unsaturated Carbonyl Compounds by Palladium (II)-Catalyzed Dehydrosilylation of Silyl Enol Ethers," J. Org. Chem. 43:1011-1013.
Kende et al. (1982), "Stereospecific Total Synthesis of Ajugarin-IV," Tet. Letts. 23:1751-1754.
Kim et al. (1994), "A new hydroxyethylamine class of HIV-1 protease inhibitors with high antiviral potency and oral bioavailabilty," Bioorg. Med. Chem. Letts. 4(19):2273-2278.
Licht, D. et al. (1992), "Correlation of the Conformation of a Modified Ribonuclease Octapeptide, Homologous to Peptide T, with Its Ability to Indice CD4-Dependent Monocyte Chemotaxis," J. Protein Chem. 11:475-481.
Marastoni et al. (1992), "A cyclic peptide T anaogue with high chrmotactic activity," Eur. J. Med. Chem. 27:383-389.
Marshall et al. (1970), "The Stereoselective Total Synthesis of Racemic Nootkatone," Tetrahedron Lett., No. 15, p. 1239.
McDougal et al. (1985), "Immunoassay for the dettection and Quantitation of Infectious Human Retrovirus, Lymphadenopathy-Associated Virus (LAV)," J. Immun. Meth. 76:171-183.
McMurry et al. (1976), "Ester Cleavages Via SN2-Type Dealkylation," Org. React. 24:187-224.
Oikawa et al. (1975), "An Application of Reactions of .beta.-Ketosulfoxides to Estrone Synthesis," Chem. Pharm. Bull. 23:2466-2467.
Oritani et al. (1984), "Enantioselectivity of Microbial Hydrolysis of (.+-.)-Decahydro-2-napththyl Acetatos. Preparations and Absolute Configurations of Chiral Decahydro2-naththols," J. Org. Chem. 49:3689-3694.
Pert et al. (1986), "Octapeptides deduced from the neuropeptide receptor-like pattern of antigen T4 in brain potently inhibit human immunodeficiency virus receptor binding and T-cell infectivity," Proc. Natl. Acad. Sci. USA 83:9254-9258.
Roberts et al. (1990), "Rational Design of Peptide-Based HIV Proteinase Inhibitors," Science 248:358-361.
Ruff et al. (1987), "CD4 receptor binding peptides that block HIV infectivity cause human monocyte chemotaxis," FEBS Lett. 211:17-22.
Ruff et al. (Sep. 26, 1987), "Peptide T.sub.[4-8] is Core HIV Envelope Sequence Required for CD4 Receptor Attachment," Lancet, p. 751.
Ruff et al. (1991), "Pharmacokinetics of Peptide T in Patients with Acquired Immunodeficiency Syndrome (AIDS)," Prog. Neuro-Psychopharmacol. & Biol. Psychiat. 15:791-801.
Schinazi et al. (1986), "Delayed Treatment with Combinations of Antiviral Drugs in Mice Infected with Herpes Simplex Virus and Application of the Median Effect Method of Analysis," Antimicrob. Agents Chemother. 30:491-498.
Schinazi et al. (1988), "Combinations of Isoprinosine and 3'-Azido-3'-Deoxythymidine in Lymphocytes Infected with Human Immunodeficiency Virus Type 1," Agents Chemother. 32:1784-1787.
Sodroski et al. (Jun. 20, 1987), "HIV Envelope-CD4 Interaction Not Inhibited by Synthetic Octaptpdies," Lancet, pp. 1428-1429.
Spira et al. (1987), "Micromethod for Assaying Reverse Transcriptase of Human T-Cell Lymphotropic Virus Type III/Lymphadenopathy-Associated Virus," J. Clin. Microbiol. 25:97-99.
Tsuda, Y. and Sakai, Y. (1981), "Efficient Dealkoxycarbonylation of Some .beta.-Ketoesters by Halides of Group IIa Metals," Synthesis, pp. 119-120.
Abajian Henry B.
Hlavka Joseph J.
Kende Andrew S.
Pincus Matthew R.
Innapharma, Inc.
Kumar Shailendra
LandOfFree
Peptidomimetics for the treatment of HIV infection does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptidomimetics for the treatment of HIV infection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptidomimetics for the treatment of HIV infection will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1222612